Once-Weekly Semaglutide in Adults with Overweight or Obesity.

John P H WildingRachel L BatterhamSalvatore CalannaMelanie DaviesLuc F Van GaalIldiko LingvayBarbara M McGowanJulio RosenstockMarie T D TranThomas A WaddenSean WhartonKoutaro YokoteNiels ZeuthenRobert F Kushnernull null

Published in: The New England journal of medicine (2021)

In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight. (Funded by Novo Nordisk; STEP 1 ClinicalTrials.gov number, NCT03548935).

Keyphrases

weight loss
body weight
weight gain
metabolic syndrome
insulin resistance
physical activity
randomized controlled trial
type diabetes
high fat diet induced
body mass index
cardiovascular disease